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Between February 2005 and May 2006,
we undertook an in-depth, broad-ranging,
independent external review of The Spe-
cial Programme for Research and Train-
ing in Tropical Diseases (TDR). TDR,
based in Geneva, was created 30 years
ago, with the World Health Organization
as its executing agency and the World
Bank and United Nations Development
Programme (UNDP) as initial co-sponsors,
with the United Nations Children’s Fund
(UNICEF) being added in 2003. Its
mandate to address research and training
in neglected tropical diseases made it a
pioneer in its first two decades. But the
landscape has changed enormously since
its inception, with new sources of funding,
different disease patterns, and greater
capacity for research and training within
disease-endemic countries. Therefore, the
Joint Coordinating Board (JCB), TDR’s
main governing body, requested that this
Fourth External Review focus on helping
it develop a relevant vision for a future role
in this shifting environment. We consid-
ered TDR’s past and present perfor-
mance, and its strengths and weaknesses,
in order to suggest ways forward.
Because of the nature of TDR’s work,
especially with its many partners, it is
difficult adequately to capture the breadth
and depth of its accomplishments in brief.
We approached the review as a ‘‘case
study’’ [1] guided by the principles of
qualitative data collection and analysis.
Data were obtained from previous exter-
nal reviews, internal documents, a man-
agement review commissioned by the
World Bank, two commissioned papers
[2,3], and other sources. Our main data,
however, were from interviews with over
250 people, of whom about 150 were key
informants from all major stakeholder
groups who participated in face-to-face,
in-depth, open-ended interviews, using an
interview guide developed for this pur-
pose. Interviewees included TDR staff,
including its current director, Dr. Robert
Ridley; members of its governing bodies;
former directors (Drs. Adetokunbe Lucas
[1976–86], Tore Godal [1986–98], and
Carlos Morel [1998–2003]; staff of co-
sponsor organizations, donor countries,
funding agencies, public–private partner-
ships (PPPs), philanthropies and other
global health organizations; countries’
representatives; and TDR alumni. We
visited various regions to talk to stakehold-
ers and to study institutions, and examined
cases illustrative of TDR’s work and its
relations with others working in global
health research and training. Additionally,
we made observations of the workings of
its various governing bodies and advisory
groups, and the Secretariat in Geneva,
where our executive secretary was based.
We began by asking, Is the original
mandate of TDR still valid? Can others
discharge this mandate better? What
would happen if TDR ceased to exist? If
it were to be re-invented for the future,
what would the new TDR look like? TDR
was given an opportunity to submit
comments. These general questions were
supplemented by specific ones tailored to
particular informants. All were asked to
give examples to support their views. The
comprehensive material was submitted to
a thematic content analysis on the basis of
which a taxonomy of issues was developed.
Further analyses built on this taxonomy
and on continuing discussions and regular
‘‘reality checks’’ with informants. The final
130–page report was completed at the end
of May 2006 and is now available on-line,
both as a full report [4] and an executive
summary [5].
Findings
In our situational analysis, we examined
the double mandate of TDR for research
and training. Research capacity strength-
ening (RCS) remains one of TDR’s core
distinguishing features,and has been tre-
mendously important for a whole genera-
tion of scientists in disease-endemic coun-
tries (DECs). However, we found that a
gradual shift in TDR’s funding has
occurred: resources earmarked for re-
search and product development have
increased while resources for RCS have
stagnated. Efforts were made to main-
stream RCS and to include training within
product development, but this was not
effective. RCS funding was diluted be-
cause of the heavy focus on product-
oriented capacity building. A renewed
commitment to this key function is needed
to better coordinate RCS; to leverage new
sources of funding and new partners; and
to supplement individual training with
institutional capacity building tailored to
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is mainly framed in terms of diseases, as its
name suggests. In the 30 years since its
inception, TDR’s portfolio of diseases has
grown from five to 10 (see Table 1).
We found differing opinions on whether
there should be a fixed list of diseases for
TDR to address, and if so, which ones.
Many of our interviewees suggested that
TDR needs to have greater flexibility in
this regard and underlined the importance
of disease interactions and common con-
trol strategies. Moreover, we noted an
increasing emphasis on ‘‘neglected popu-
lations’’, not just ‘‘neglected diseases’’, as
the main focus of TDR’s future work.
Refocusing along these lines will require a
broader, more flexible approach to health
as a social as well as a medical issue. TDR
was a pioneer in supporting trans-disci-
plinary research [6], but its social sciences
staff has remained small. There was only
one scientist in the Social, Economic and
Behavioural Unit at the time of our
review. The ambition to conduct basic
research on issues such as social inequality
and health sector reform, while also
meeting the growing need for intervention
research, cannot be realized without
substantial strengthening of social science
and continued commitment to trans-disci-
plinary research. Overall, we concluded
that TDR has been extremely successful in
the past. It worked with industry partners
to shape the development of new products,
including eflornithine for African trypano-
somiasis, praziquantel for schistosomiasis,
and various drug combination and formu-
lation innovations for malaria. TDR also
sponsored the critical studies establishing
the efficacy of insecticide-impregnated
bednets for control of malaria. Its more
recent successes include the registration of
miltefosine for visceral leishmaniasis, facil-
itation of the sequencing of the Anopheles
gambiae genome, and provision of evidence
for artemisinin-based combination treat-
ments for malaria control policy. Its
important social science intervention re-
search includes developing a strategy for
managing malaria ‘‘close to home’’, and
contributions in the use of ivermectin for
community control of onchocerchiasis in
areas with high loiasis. Most importantly,
it has played a major role in building
individual and institutional research ca-
pacity in the developing world (see [7] for
a full list of its accomplishments).
Today, TDR continues to be moder-
ately successful, but its influence has
waned because of the very changed
external landscape. There are many more
players and initiatives in neglected diseases
research. There are huge new funding
sources such as the Bill & Melinda Gates
Foundation, the Wellcome Trust, the
United States National Institutes of
Health, and others; there are PPPs in-
volved in product development [8,9];
there are other organizations (e.g., Council
on Health Research for Development and
Global Forum for Health Research) that
focus on various research-related issues,
including advocacy for health research in
developing countries; and there is more
research and training conducted in, and
by, DECs themselves.
Thus, the future role of TDR at the
time of our review was unclear. There was
a danger of TDR becoming marginalized
as large infusions of funds went elsewhere,
for example into product-developing PPPs
such as Medicines for Malaria Venture,
which had been created with TDR’s help.
We found that TDR had not managed to
partner well with the philanthropies and
PPPs or to define respective functions and
tasks, or build sufficient linkages and
mutual agreements for collaboration.
Table 1. The Ten Diseases in TDR’s
Portfolio.
1. Leishmaniasis
2. Schistosomiasis
3. Onchocerciasis
4. Lymphatic filariasis
5. Chagas disease
6. Malaria
7. Leprosy
8. African trypanosomiasis
9. Tuberculosis
10. Dengue
1–8 were the original diseases defined in 1975. The
Third External Review was carried out in 1998; TB
and dengue were added in 1999. Diagnostics for
sexually transmitted diseases were added in 2000.
After the Fourth External Review, the Joint
Coordinating Board (30th session, 2007) approved
TDR’s new Ten Year Vision and Strategy
encompassing ‘‘infectious diseases of poverty’’.
doi:10.1371/journal.pntd.0000314.t001
Box 1. TDR’s Strengths and Weaknesses
Strengths
N Its nature as a multilateral, inter-governmental agency with multiple co-sponsors.
N Its many competent, caring staff, many of whom are from disease-endemic
countries (DECs).
N Its track record (TDR is perceived and emulated as ‘‘a star’’, ‘‘a model’’).
N The respect that people have for TDR.
N Its association with WHO, adding to its credibility, especially in DECs, and giving
it entry into countries.
N Its record in research capacity strengthening.
N Its values (neutral, science-based, public health orientation, voice of DECs,
focused on equity, and access).
N Its many supporters, including its co-sponsors, governing bodies, and alumni.
N Its convening, agenda setting, catalytic and midwifery functions, and leveraging
capacity.
N PPPs have in their ‘‘pipelines’’ a number of products—drugs, vaccines,
diagnostics—that will need efficient clinical trialing, testing, evaluation, and
other forms of intervention research that TDR is well placed to provide.
Weaknesses
N Its place in the 21st century among others engaged in ‘‘tropical diseases’’
research and research capacity strengthening is unclear.
N It is embattled by the external environment.
N The voices of DECs could be better represented.
N It is struggling against WHO’s and its own bureaucracy.
N It often does not relate well and productively with other entities addressing
global health issues.
N It does not sell itself well, especially in articulating its unique strengths.
N It does not make good use of its co-sponsors’ resources.
N It has unaddressed management problems.
N In-house creativity is under-emphasized and under-utilized.
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about its relationship with the WHO. It
was often over-administered and under-
managed, and had sub-optimal in-house
communication, inefficient budgetary pro-
cedures, inadequate funds, and insufficient
discretion to use many of these funds.
Some of these problems were caused by
forces beyond TDR’s control. Much of its
staff was demoralized and felt ‘‘disempow-
ered’’, and its strategic processes needed to
be less opaque. It needed to exert more
effort in objectively evaluating its work.
Our report documents and discusses the
strengths and weaknesses of TDR,
summed up in Box 1 (based on [4]). On
balance, we found immense support for
TDR and widespread conviction that its
problems could be addressed and reme-
died. We concluded that TDR was an
extremely valuable organization that could
play critical roles not adequately filled by
any other organization. Identifying these
roles is particularly relevant in the
changed external landscape, where new
needs are emerging that can only be met
by an organization like TDR. Stakehold-
ers were keen to see it develop a strong
new vision and to evolve and grow. To do
this TDR needed to undergo a process of
re-orientation and renewal. It must con-
tinue to be supported by all stakeholders
with significant increases in funding, and it
must have dynamic leadership. The big-
gest danger was that TDR would resist
significant change, believing that it will be
the best in the future because it was the
best in the past.
Recommendations
TDR’s mandate and institutional base
remained largely valid, but needed to be
re-interpreted in light of the radically
changed external landscape. Evolution
and growth must be in both form and
function—and form must serve function.
Our recommendations for these changes
are summarized in Box 2 (based on [4]).
We believe that TDR should concentrate
on the neglected diseases and health needs
of the most needy populations. In the
changed landscape, we saw four areas
where TDR has a special role to play: 1)
Stewardship (including research advocacy
and coordination) is a function best
undertaken by a neutral international
organization, such as TDR, that can
maintain an overview of the increasingly
complex scene; 2) Expanded intervention
research is crucial in order to ensure that
new products and strategies actually reach
those who need them; 3) Research capac-
ity strengthening for the future is necessary
Box 2. Summary of Major Recommendations
The 4th External Review Committee recommends that TDR:
N Is supported by all stakeholders to evolve and grow to a renewed mandate that
addresses the very neglected diseases and the health needs of the most needy
populations.
N Undertakes a major re-orientation and stakeholder engagement exercise in the
very near future. The agenda should include proposals for negotiated/
contracted strategic alliances and partnerships with major stakeholders;
proposals to secure increased funding; discussions with co-sponsors on how
best to make use of the latter’s resources; a mechanism for regular
consultations to coordinate approaches and investments.
N Creates four functional areas as follows:
1. Stewardship, Research Advocacy, and Coordination: ar o l et h a tn oo t h e r
institution at present can legitimately fulfill; requires a cultural change in TDR.
2. Expanded Intervention Research: rapidly scale up; include all neglected
diseases and health needs of the most needy; play a key role in the
evaluation of new products from Phase I clinical trials through Phase IV
post-marketing studies; study the effectiveness of intervention strategies in
real-life situations; emphasize policy and social, economic, and behavioural
research; clarify and reinforce links with WHO’s control programmes.
3. Research Capacity Strengthening for the Future: foster not only technical
skills but also competences in research oversight and management, as well
as ethics; reinvigorate efforts to strengthen and collaborate with research
training institutions in the South and build more effectively on the RCS
potential of its networks of alumni, and of scientists in the diaspora.
4. Research and Development for Physical Products: reduce R&D for physical
products to address only the few very neglected diseases (or areas of
neglected diseases) that others are not addressing adequately.
N Decentralizes minimally: create small, region-based TDR Teams to increase
alignment with countries’ needs and priorities, ownership, sustainability, and
ability to draw on the local resources of all TDR co-sponsors and alignment with
their country focus.
N Develops a strategic staffing plan: take into account the needs of the new TDR
and its future functions and structure.
N Considers enlarging the co-sponsor group: reflect the key players in global
health and the new sources of major funding for global health research, RCS,
and public health interventions.
N Considers ways to improve its relations with PPPs, the private sector,
philanthropies, and others who have similar or overlapping mandates.
N Improves its relationship with WHO, its executing agency: clarify unresolved
issues in the Memorandum of Understanding and negotiate a comprehensive
Administrative Structural Agreement to make its administrative and financial
management more efficient and transparent, and to enable changes needed for
renewal and implementation of its new directions.
N Improves its governance mechanisms: clarify the relationships between its
components and allow for bigger support roles e.g., advocacy and resource
mobilization by the Joint Coordinating Board, increasing the latter’s engage-
ment with the Programme and fully reclaiming its governance role, with
definitive authority on priority-setting and an active role in policy-making.
N Has strong leadership: the next director should be given greater authority,
independence, and seniority of decision-making (with corresponding higher
salary level); leadership qualities include being a good scientist; being a
decisive, nimble, bold, and courageous visionary; possessing strong diplomatic
and political skills; being a great communicator who is internationally
respected; being able to take responsibility for major decisions; being
comfortable working with all stakeholders; being able to live and work in
disease-endemic countries; and being able ultimately to manage the whole TDR
Secretariat and overrule petty bureaucracy.
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systems and collaborative networks in the
South and North; and 4) Research and
development for physical products should
focus only on those neglected diseases (or
areas of neglected diseases) that others
(such as the PPPs) are not adequately
addressing.
Successful reorientation around these
functional areas requires far-reaching in-
stitutional transformation. We proposed
changes within TDR’s Secretariat, in
TDR’s governance, in its co-sponsor
group, in its relationship to WHO, in its
way of working with regions and countries,
and in its relations to philanthropies, PPPs,
the private sector, and other agencies with
mandates overlapping TDR’s. Only
through forging new partnerships will
TDR become a flourishing organic part
of the new landscape. It must mobilize
new resources to evolve. If TDR and its
many supporters commit themselves to
change, TDR can be re-energized for
another 30 years.
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